S/GSK1349572: Phase IIb data

In the ongoing, double-blind, dose-ranging Phase IIb SPRING-1 trial in 205 treatment-naïve HIV patients, once-daily 10, 25 and 50 mg S/GSK1349572 reduced mean HIV-1 RNA levels from baseline to week 2 by 2.39, 2.37 and 2.4 log10 copies/mL, respectively, vs. 1.93 log10 copies/mL for once-daily 600 mg Sustiva efavirenz. Additionally, the proportion of patients with HIV-1 RNA levels <50 copies/mL at week 16 was 96%, 92% and 90% for low-, mid- and high-dose S/GSK1349572, respectively, vs. 60% for Sustiva. Time to undetectable viral load (<50 copies/mL) also was significantly shorter for all S/GSK1349572 arms vs. Sustiva (p<0.001 for all). Median increases in CD4+ T cells from baseline to week 16 for S/GSK1349572 were 153, 176 and 160 cell/mm 3, respectively, vs. 115 cells/mm 3 for Sustiva. Patients received Epzicom abacavir/lamivudine or Truvada emtricitabine/tenofovir in combination with either S/GSK1349572 or Sustiva. Data were presented at the International AIDS Conference in Vienna. ...